Lumida
/AIRS
⌘K
AirSculpt Technologies Inc

AirSculpt Technologies Inc

AIRS
$2.42USD↑+0.83%+0.02 today

MARKET CAP

174.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$2
$12

AI Summary

Stalk
StalkMedium

In Stage 2 Advancing, AIRS retains a medium-term bullish bias underpinned by higher highs/lows and support at the rising 50 DMA, but short-term timing is neutral as price pulls back into the 9/21/50 EMA zone. Execution should be deferred around this support range, seeking evidence of acceptance before committing. Primary risk is a decisive break below the 50 DMA and prior higher-low, which would invalidate the bullish outlook.

  • ↑Pursuing GLP-1 market, aiming $100M+ revenue from post-treatment aesthetics
  • ↑Same-center cases up 21pp YoY, stabilizing core body-contouring revenue
  • ↓Earnings yield at -1.94% indicates inability to generate shareholder returns
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

AirSculpt Technologies, Inc. (NASDAQ: AIRS) specializes in minimally invasive body contouring procedures, uniquely positioned to leverage the growing market influenced by GLP-1 medications. The company operates in the aesthetic healthcare sector with a focus on enhancing patient services and expanding market presence through innovative procedural offerings. As a player in the rising anti-aging trend, particularly among the baby boomer demographic, AirSculpt is tapping into a lucrative niche within elective medical procedures.

Bull says

  • ↑Pursuing GLP-1 market, aiming $100M+ revenue from post-treatment aesthetics
  • ↑Same-center cases up 21pp YoY, stabilizing core body-contouring revenue
  • ↑Reduced gross debt by $30M, enhancing liquidity and financial flexibility
  • ↑Record-high consultation leads from targeted GLP-1 marketing
  • ↑Introduced skin tightening service to diversify revenue streams
  • ↑Book-to-Price ratio at 0.61 suggests potential undervaluation

Bear says

  • ↓Earnings yield at -1.94% indicates inability to generate shareholder returns
  • ↓CAC rose to $3,500 per case, eroding profitability
  • ↓Q2 revenue down 2.5% YoY at $42.9M, showing revenue pressure
  • ↓Volatility score extreme, leading to wild share price swings
  • ↓Analyst sentiment negative; short interest at 49.8% signals bearish consensus
  • ↓GLP-1 coverage cuts could dent patient volumes and procedure demand

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-11-2026neutral

Transcript signals

Bull points

  • We will do expect, again, a reduction in our same store decline. We still expect Q3 to be declining, but not as significant as Q1 and Q2. And then as we kind of exit into Q4, we'll start to see modest, or I say modest, significant improvement.
  • the second quarter of fiscal 2025
  • overview of our second quarter performance

Bear points

  • However, London continues to be cash flow negative.
  • revenue was $44 million, declining .7% from the second quarter of 2024, and adjusted EBITDA was $5.8 million for a margin of .3% versus $6.9 million for a margin of .5% in the second quarter of 2024.
  • The decline in revenue was driven by lower case volume, which reflects the challenging macro environment. Same store revenue, which does not include new centers, improved marginally from the first quarter and declined approximately 22% over the prior year quarter.
Read full transcript analysis ›